FDA Claims Six of Qiagen's Molecular Dxs Should Have Undergone Agency Review

NEW YORK (GenomeWeb News) — The US Food and Drug Administration has sent a letter to Qiagen warning it that certain of its molecular diagnostics currently sold in the US do not have regulatory approval.

In an Oct. 2 letter to Qiagen CEO Peer Schatz, the FDA said six diagnostic products Qiagen developed are improperly marketed and require regulatory review by the agency. On its we site, Qiagen stresses that the products — tests for herpes virus, lime disease, parvovirus, Chlamydia, and malaria — are designed for use in CLIA labs and therefore do not require FDA oversight.

The FDA, on the other hand, claims that because the tests are packaged with instructions they are subject to agency review.

Products affected include Artus CMV PCR, C. Trachomatis PCR, C. Trachomatis Plus PCR, Parvo B19 PCR, Borrelia PCR, and Malaria PCR analyte specific reagents.

BioBOOM Op/Ed: Predict that this is going to hurt as the big difference in thier growth the past quarter verses the other competitors was primarily due to efforts in MDx


Anonymous said...

It is not Lime disease but Lyme disease or borrelia burgdorfi, the fastest growing infectious disease in the world at the moment despite government cover up

Diagnostic Products said...

We are suppliers of Diagnostic Products, Medical Products, Diabetic Supplies, Maternity Care, Dietary Supplements offered at discount prices.